Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

(STAT News) How a dinner in Paris revived talks for Sanofi’s $9.5 billion deal for Blueprint Medicines. For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life ...

From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

A high-level overview of Blueprint Medicines Corporation (BPMC) stock. View (BPMC) real-time stock price, chart, news, analysis, analyst reviews and more.

Sanofi has entered into an agreement to acquire Blueprint Medicines for $129 per share, or about $9.1 billion. Additional contingent value rights bring the total potential deal value to $9.5 billion.

Learn about the executive team and board of directors at Blueprint Medicines Corp (BPMC:XNAS) and review their bios and compensation over the latest fiscal years.

The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, ...

Apple’s efforts to expand its manufacturing footprint in India have hit a roadblock. Foxconn, the tech giant’s key assembly partner, has quietly recalled a la ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...